Quick Facts

• Approved Uses: Relief of symptoms associated with seasonal and perennial allergic rhinitis.
• Additional Use: Management of the skin manifestations of chronic hives (urticaria).

Pollezin, which contains levocetirizine, is a medication that may provide relief for a range of allergy-related symptoms. Its primary therapeutic domains include managing the discomfort associated with allergic rhinitis, which can be seasonal or year-round. This involves addressing common symptoms such as sneezing, runny nose, and itchy, watery eyes.

The medication is also utilized in the management of chronic idiopathic urticaria (hives). For this condition, Pollezin may help reduce the appearance of hives and the associated itching. Levocetirizine is a recognized option for these indications in adults and certain pediatric populations.

This medication is available in both prescription and over-the-counter forms. Patients should consult their healthcare provider to ensure its use is appropriate for their specific needs and health profile. It is a suitable option for temporary relief of allergy symptoms and management of chronic hives.

Who can and cannot use Pollezin?

The use of Pollezin (levocetirizine) is determined by a patient’s age and underlying health conditions, particularly kidney function, as stipulated by regulatory documents.

Contraindicated Populations (Must Not Use)

• Patients with end-stage renal disease (creatinine clearance less than 10 mL/min) or those undergoing hemodialysis.
• Pediatric patients aged 6 months to 11 years with any degree of impaired renal function.
• Individuals with a known hypersensitivity or allergy to levocetirizine, any of the drug's ingredients, or to cetirizine.

Restricted Use and Special Consideration

This medicine is primarily approved for use in adults and children 6 months of age and older, with use in children under 6 years restricted to the oral solution formulation.

Pollezin Interactions with Other Medicines and Products

This section summarizes interaction information for Pollezin (Levocetirizine dihydrochloride) as documented in official government regulatory documents.

Documented Pharmacodynamic and PK Interactions

Pollezin's primary interaction is a pharmacodynamic reinforcement with substances that depress the Central Nervous System (CNS).

Food and Population-Specific Notes

The absorption of Pollezin is influenced by food, but the total amount absorbed is unchanged. Consumption with food only decreases the rate of absorption, delaying the time to maximum concentration ( T max) while the total amount absorbed ( AUC) is unaffected.

Patients with impaired renal function are identified as a population with a potentially greater risk of adverse reactions resulting from altered drug clearance or exposure, as Levocetirizine is primarily excreted by the kidneys.

Regulatory studies conducted with the parent substance showed no clinically relevant adverse interactions with agents like Azithromycin, Cimetidine, Erythromycin, Ketoconazole, Theophylline, or Pseudoephedrine.

Pollezin (levocetirizine) functions as a highly selective, second-generation inverse agonist of the Histamine H1 receptor. This receptor is a key mediator in inflammatory and hypersensitivity reactions, being expressed across the respiratory tract, vascular endothelium, and skin. Pollezin does not act as a simple competitive antagonist; instead, it binds to the H1 receptor and stabilizes its inactive conformational state. This specific interaction shifts the receptor's equilibrium away from its naturally occurring active state, effectively reducing its constitutive activity. By stabilizing the inactive H1 receptor, Pollezin interrupts the normal signal transduction cascade initiated by histamine binding. This inhibition prevents histamine from triggering Gq protein coupling and the subsequent intracellular increase in IP3 (Inositol Trisphosphate) and DAG (Diacylglycerol). The downstream system-level physiological consequence of this molecular action is the modulation of cellular effects mediated by the H1 receptor, specifically resulting in the diminished activation of NF-κB and the reduction of vascular endothelial permeability and smooth muscle contraction.

Pollezin is a medicine intended for oral administration only, available as a 5 mg film-coated tablet and an oral solution (2.5 mg per 5 mL). The standard regimen for adults and adolescents (12 years and older) is 5 mg taken once daily. This dose is typically administered in the evening and is the maximum recommended daily intake. A dose of 2.5 mg once daily may be utilized when adequate control of symptoms is achieved. The tablet is manufactured with a score line, confirming it can be divided to facilitate the administration of the 2.5 mg dose.

Whether taking the tablet or the oral solution, the medicine may be consumed with or without food. Treatment duration is determined by the pattern of symptoms. For intermittent conditions, use is symptom-driven, allowing administration to be suspended when symptoms resolve and restarted upon recurrence. For persistent conditions, treatment may be continuous, and courses can extend for periods of at least six months.

A key procedural requirement is the adjustment of the dose for patients with reduced kidney function. The dosing interval must be modified based on creatinine clearance (CLCR). For instance, patients with moderate renal impairment (CLCR 30–50 mL/min) are administered 2.5 mg every other day. In contrast, no dose adjustment is needed for patients who have only hepatic impairment. For children between 6 and 11 years, the official dose is 2.5 mg once daily.

Research Evidence / Overview of Studies for Pollezin

1. Research Evidence for Allergic Rhinitis (Seasonal and Perennial)

Research explored the use of Pollezin (levocetirizine) in managing conditions characterized by fluctuating or episodic manifestations such as seasonal and year-round allergic rhinitis. This research includes numerous short-term and intermediate-term randomized, double-blind, placebo-controlled trials (RCTs). These studies was evaluated in settings comparing the medicine against an inactive substance (placebo) or against other second-generation antihistamines. The studies monitored outcomes related to physical discomfort by measuring changes in nasal symptoms, such as sneezing and runny nose, using standardized scoring systems. Researchers also applied in studies examining patient-reported experiences regarding quality of life and outcomes reflecting daily functioning or activity level.

Findings describe patterns observed in the studies, where changes in symptom score measurements were reported over treatment periods of four to six weeks. However, one specific study in seasonal allergic rhinitis described patterns observed where the primary symptom outcome was observed to align with measurements reported for placebo, an observation that researchers noted was unlike prior study findings.

2. Research Evidence for Chronic Urticaria (Hives)

Pollezin was studied for conditions associated with acute or disruptive episodes such as chronic urticaria (hives). Research primarily utilized short-term (four-to-six-week) randomized, controlled trials. These studies monitored outcomes linked to inflammatory or irritative states by measuring how the severity of itching (pruritus) and the number and size of skin wheals (rashes) evolved over the defined study intervals. Patient-reported outcomes describing perceived discomfort were also key outcomes examined in these trials.

3. Long-Term Studies and Observation Periods

Pollezin was evaluated in a few longer-duration studies, primarily for persistent allergic rhinitis, with some trials extending their follow-up durations up to six months. However, there is limited information for long-term outcomes beyond the six-month study periods. Most core data and studies focused on chronic hives are based on short-term follow-up durations. Therefore, long-term effects are not fully established, and certainty remains low regarding the durability of observed symptom changes over extended use.

4. Evidence in Special Populations

Pollezin was studied for allergic rhinitis and chronic urticaria in children across various age groups. Studies involving pediatric patients explored symptom changes using adapted measures. Despite this, data for certain groups remain insufficient. For instance, a comprehensive clinical evaluation of the medicine for chronic urticaria in children is not fully established, as many studies have focused mainly on adult patients.

Common questions about Pollezin (FAQ)

Q: How quickly does Pollezin usually start working?

Studies and official information indicate that the medicine is characterized by a rapid absorption profile. Peak concentrations are typically reached in the blood approximately 54 minutes after taking the tablet. Researchers have observed that antihistaminic activity may begin within one hour of administration.

Q: How long does the effect of Pollezin last?

According to the official product information, the medicine is characterized by a half-life of 8 to 9 hours in healthy adults. Studies have reported that significant peripheral antihistaminic activity may still be observed for up to 28 hours after a single dose.

Q: Is Pollezin safe to use during pregnancy?

Official US regulatory documents place this medicine in Pregnancy Category B. This classification means that while animal reproduction studies have generally not shown a risk to the fetus, adequate and well-controlled studies specifically conducted in pregnant women are not available.

Q: What are the official recommendations about Pollezin and breastfeeding?

Regulatory documents advise against using this medicine while breastfeeding. This precaution is based on the expectation that the medicine will be excreted into human milk. The official safety profile for the nursing infant in this context is not fully established.

Q: Can Pollezin be taken on an empty stomach?

Yes, official prescribing information states that the medicine is appropriate for administration either with or without food. Taking the medicine alongside food may slightly delay the time the peak concentration is reached, but the total amount of medicine absorbed by the body remains the same.

Q: Is there a specific time of day Pollezin is usually recommended?

Official directions for adults and adolescents recommend taking the medicine once daily in the evening. This is the official guidance provided in the prescribing documents.

Q: How is Pollezin eliminated from the body?

The major way the body eliminates this medicine is via the kidneys, accounting for over 85% of the dose. It is excreted by the urinary system through a process involving both glomerular filtration and active tubular secretion.

Q: Why do people sometimes use Pollezin for conditions other than the main ones listed?

The official approved uses for this medicine, as determined by regulatory bodies, are for the relief of symptoms associated with seasonal and perennial allergic rhinitis and chronic urticaria (hives). Information concerning other uses is not detailed or contained within the official prescribing documents.

Q: Can Pollezin make me feel restless or agitated?

Official safety data lists agitation as an Uncommon side effect. Restlessness is also among the effects reported during post-marketing surveillance, though its exact frequency is officially classified as Not Known. These reports help regulatory bodies monitor effects experienced by patients.

Q: Are there any serious or rare side effects I should be aware of regarding Pollezin?

Official safety information documents Rare effects such as increased weight and tachycardia (fast heart rate). The label also documents reports of serious adverse reactions, including severe hypersensitivity events (anaphylaxis and swelling) and, less commonly, suicidal ideation, which are typically based on post-marketing reports.

Q: What happens if I miss a scheduled amount of Pollezin?

Official patient information advises that if a dose is missed, taking it when remembered is described as appropriate. However, if it is almost time for the next scheduled dose, the advice is to take only the next dose and not to take extra or double the scheduled amount.

Q: Does Pollezin interact with birth control pills?

Official studies indicate the medicine has a low extent of metabolism, meaning it is broken down very little by the liver’s main enzyme systems. This suggests a low likelihood of interaction with hormonal contraceptives; however, birth control pills are not specifically listed as an interacting agent in regulatory documents.

Q: Can Pollezin affect mental focus or concentration?

Regulatory warnings state that the medicine may cause central nervous system (CNS) depression, which may impair physical or mental abilities. Patients are officially cautioned regarding the potential for reduced mental alertness and motor coordination while using this medicine.

Q: Are there any documented cases of overdose with Pollezin?

Information for overdose management is available in official clinical guidelines and references. Overdose symptoms may include dizziness, headache, drowsiness, or agitation. In such cases, management of overdose is typically supportive.

Q: Is it possible to develop a tolerance to Pollezin over time?

Official regulatory documents and post-marketing surveillance studies that have examined long-term use do not contain specific warnings or cautions regarding the development of pharmacological tolerance to the medicine.

Q: Does Pollezin affect blood pressure?

Official documents list both low blood pressure (hypotension) and high blood pressure (hypertension) as side effects reported with the medicine, though their frequency is officially classified as Not Known or Uncommon. Tachycardia (fast heart rate) is also listed as a rare effect.

Q: Are there special considerations for Pollezin use in patients with liver issues?

Official documents state that no adjustment to the dose is needed for patients who have solely hepatic impairment (liver issues). However, adjustment is officially recommended for patients who have both hepatic and renal impairment (kidney issues).

Q: Is Pollezin safe to use before driving or operating machinery?

Regulatory warnings caution patients against engaging in activities that require complete mental alertness and motor coordination, such as operating machinery or driving a motor vehicle, until they know how the medicine affects them.

Q: Can Pollezin cause changes in appetite or weight?

Increased weight is listed as a Rare adverse reaction in official safety data. Changes in appetite, including both loss of appetite and increased appetite, have also been reported in post-marketing surveillance, though the frequency is officially classified as Not Known.

Q: Have there been any recent updates to the safety information for Pollezin?

Official safety updates have been made by regulatory bodies to include information about new onset pruritus (itching) that has been reported upon discontinuation of the medicine. This effect has usually been observed following long-term use.

Q: What does the research say about Pollezin's use for chronic conditions?

Clinical research has examined the use of the medicine for persistent allergic rhinitis and chronic urticaria (hives), with some trials extending follow-up to six months. However, official information notes that there is limited data, and long-term effects beyond these six-month periods are not fully established.

Official Storage and Disposal Requirements

These instructions define the mandatory environmental constraints and handling rules for the medicine. Disposal must follow community or pharmacy take-back procedures, or other local regulations for pharmaceutical waste.